Skip to main content

Table 1 Summary of efficacy and safety assessments carried out throughout the study

From: Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study

  Treatment period (weeks) Post-treatment period (weeks)
  SD1 2 6 10 14 18 22 26 34 42 52 4
Efficacy and safety assessments*   X X X X X X X X X X X
IBDQ assessment X        X    X  
CDAI assessment X X X X X X X X X X X  
CRP X   X   X   X X X X X X
ESR X   X   X   X X X X X X
Antibodies to IFN beta-1a X        X    X  
Thyroid function X        X    X  
Urinalysis X        X    X X
Pregnancy testing X    X   X   X    X  
  1. CDAI: Crohn's disease activity index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; IBDQ: inflammatory bowel disease questionnaire; IFN, interferon; SD1, study day 1
  2. *Safety data were obtained by monitoring adverse events/serious adverse events, concomitant medications, physical examinations, vital signs and routine analysis of blood (haematology and chemistry)